MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Preserved white matter microstructure in Parkinson’s disease patients with levodopa-induced dyskinesia: Evaluation by neurite orientation dispersion and density imaging (NODDI)

    T. Ogawa, T. Hatano, H. Takeshige, C. Andica, K. Kamagata, A. Saito, T. Koinuma, R. Nakamura, H. Iwamuro, G. Oyama, Y. Shimo, A. Umemura, M. Ito, S. Aoki, N. Hattori (Tokyo, Japan)

    Objective: Brain microstructure alteration using MRI in Parkinson's disease (PD) have not been well studied. We analysis the white matter alterations in Parkinson’s disease with…
  • 2019 International Congress

    Longitudinal Change of Substantia Nigra Hyperechogenicity in Parkinson’s Disease Cohort

    T. Toomsoo, I. Rubanovits, R. Kerner, T. Asser, M. Vähi, P. Taba (Tallinn, Estonia)

    Objective: To analyze whether the size of SN+ is differentially affected depending on disease duration. Secondly to analyze the interaction between a range of clinical…
  • 2019 International Congress

    Mindfulness Based Stress Reduction in People with Parkinson’s Disease and their Carepartners

    D. Shah, S. Mantri, J. Cooney, A. Allen, K. Durham, J. Brantley, R. Vereen, P. Hickey, B. Scott (Durham, NC, USA)

    Objective: To assess the feasibility and impact of mindfulness based stress reduction (MBSR) on people with Parkinson’s disease (PD) and their carepartners. Background: Non-motor symptoms…
  • 2019 International Congress

    Prevalence and associated risk factors of early morning off among the patients with Parkinson’s disease in China

    W. Mao, C. Han, J. An, Z. Liu, P. Chan (Beijing, China)

    Objective: To explore the prevalence and associated risk factors of early morning off (EMO) among outpatients with Parkinson’s disease (PD) in China. Background: PD is…
  • 2019 International Congress

    Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

    M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

    Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…
  • 2019 International Congress

    Safinamide: real world evidence in Toledo´s Movement Disorders Unit

    N. López-Ariztegui, MI. Morales-Casado, JC. Segundo-Rodríguez, A. Avila-Fernández, N. García-Alvarado, J. Pérez-Matos (Toledo, Spain)

    Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…
  • 2019 International Congress

    Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

    M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

    Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…
  • 2019 International Congress

    Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment

    B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

    Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…
  • 2019 International Congress

    Tremor and parkinsonism in Chromosomopathies – a systematic review

    V. Carvalho, L. Guedes (Matosinhos, Portugal)

    Objective: To review the co-occurrence of parkinsonism and tremor syndromes in patients with chromosomic disorders. Background: The landscape of genetic forms of Parkinson’s diseases (PD)…
  • 2019 International Congress

    The potential modifier effect of C9orf72 DNA methylation in C9ORF72 carriers

    JM. Laffita-Mesa, CH. Kreidy, M. Paucar, P. Svenningsson (Stockholm, Sweden)

    Objective: To develop molecular assays for determining the influence of hypermethylation on age of onset for C9ORF72 carriers. Background: Hexanucleotide repeats of GGGGCC in C9ORF72 is…
  • « Previous Page
  • 1
  • …
  • 160
  • 161
  • 162
  • 163
  • 164
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • #24475 (not found)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley